Isofol Medical (ISOFOL) Stora Aktiedagarna 2026 summary

Key presentations and scientific insights

• Highlighted arfolitixorin as a next-generation folate drug designed to enhance 5-FU-based chemotherapy, with a focus on metastatic colorectal cancer (mCRC), the third most common cancer globally.

• Demonstrated that arfolitixorin achieves higher concentrations of active folate in tumors compared to leucovorin, leading to improved TS inhibition and potential for increased efficacy with higher doses.

• Preclinical and early clinical data show a strong dose-response relationship for arfolitixorin, distinguishing it from standard leucovorin, whose efficacy plateaus at higher doses.

• Interim results from the ongoing phase 1b/2 trial indicate all patients have responded to treatment, with significant tumor shrinkage and some patients eligible for surgery, an unexpected outcome in RAS-mutated mCRC.

• Safety profile remains favorable at higher doses, with no dose-limiting toxicities observed to date.

Strategic plans and partnerships

• Ongoing phase 1b/2 clinical trial in Europe and Japan aims to optimize dosing and confirm efficacy in first-line mCRC, with results expected through 2027.

• Collaborations established with leading institutions such as Charité Universitätsmedizin Berlin and a global advisory board of oncology experts.

• Key partnerships in place with Merck and Solasia, and licensing agreements for Japan and Canada to expand market reach.

• Strong intellectual property protection with patents covering composition, method of use, and new dosing regimens, extending into the 2040s.

Market opportunity and financial outlook

• Addressable market includes 95% of mCRC patients, with arfolitixorin positioned as the only new first-line replacement for leucovorin.

• Global CRC pharmaceutical market projected to grow from $13.5B in 2025 to $16.9B by 2030; mCRC segment expected to reach $7.3B.

• Blockbuster sales potential in the US alone, with gross yearly sales for mCRC estimated at $1B, assuming >50% market penetration and premium pricing.

• Additional revenue opportunities anticipated from expansion into other solid tumors and international markets.